目录产品 » TRAIL R1/DR4/TNFRSF10A hFc Chimera, Human
Manual
Manual
COAs

TRAIL R1/DR4/TNFRSF10A hFc Chimera, Human

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis selectively via its interaction with the death receptors TRAILR1/DR4 and TRAILR2/DR5 in a wide range of cancers, while sparing normal cells. Despite its tremendous potential for cancer therapeutics, the translation of TRAIL into the clinic has been confounded by TRAIL-resistant cancer populations.
￥2400 在线订购包邮(港澳台除外)
Z05910-100

咨询产品问题
产品简介
Species Human
Protein Construction
TRAIL R1/DR4/TNFRSF10A (Ala24-Asn239)
Accession # O00220		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 48.8 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
返回

图例
TRAIL R1/DR4/TNFRSF10A HFc Chimera, Human

Immobilized Human Trail, No Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for TRAIL R1/DR4/TNFRSF10A hFc Chimera, Human, hFc Tag with the EC50 of 11.1ng/ml determined by ELISA. »

TRAIL R1/DR4/TNFRSF10A HFc Chimera, Human

The purity of TRAIL R1/DR4/TNFRSF10A hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »

TRAIL R1/DR4/TNFRSF10A HFc Chimera, Human

TRAIL R1/DR4/TNFRSF10A hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

技术背景
Target Background Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis selectively via its interaction with the death receptors TRAILR1/DR4 and TRAILR2/DR5 in a wide range of cancers, while sparing normal cells. Despite its tremendous potential for cancer therapeutics, the translation of TRAIL into the clinic has been confounded by TRAIL-resistant cancer populations.
Synonyms DR4; CD261; TNFRSF10A; TRAIL-R; APO2; TRAIL R1; MGC9365
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.